These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 4349136)

  • 1. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia.
    Eaton BP; Nye WH
    J Lab Clin Med; 1973 May; 81(5):682-95. PubMed ID: 4349136
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
    Bagdade JD; Bierman EL; Porte D
    Diabetes; 1971 Oct; 20(10):664-72. PubMed ID: 5110698
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
    Schwandt P; Weisweiler P; Neureuther G; Wilkening J
    MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
    Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
    Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
    Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
    Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of electrophoretic mobility of very low density lipoproteins: role of slower migrating species in endogenous hypertriglyceridemia (type IV hyperlipoproteinemia) and broad-beta disease (type III).
    Hazzard ER; Bierman EL
    J Lab Clin Med; 1975 Aug; 86(2):239-52. PubMed ID: 168277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
    Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
    Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altering lipid patterns in adult males.
    Appelbaum JJ; Amundsen MA; Perkin DK
    J Occup Med; 1974 Aug; 16(8):539-42. PubMed ID: 4367267
    [No Abstract]   [Full Text] [Related]  

  • 9. [Xanthomatosis as a symptom of hyperlipidemic metabolic disorders. Relationship of the morphological picture to the lipid of three patients].
    Rufli T; Stähelin H
    Dermatologica; 1972; 144(5):270-82. PubMed ID: 4351630
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P; Schwandt P
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():398-401. PubMed ID: 206058
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
    Enger SC; Johnsen V; Samuelsen A; Laws EA
    Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipoproteins, glucose tolerance and insulin secretion].
    Debry G; Mejean L; Drouin P; Villaume C; Pointel JP; Vernhes G
    Ann Nutr Aliment; 1979; 33(1):113-34. PubMed ID: 382956
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of a combination treatment with clofibrate on the lipoprotein pattern of endogenous hypertriglyceridemia].
    Vogelberg KH; Althoff B; Heggen EM; Thesseling W
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():832-5. PubMed ID: 196437
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of clofibrate therapy on the glucagon and insulin secretion as well as on the glucose tolerance in patients with type IV hyperlipoproteinemia].
    Drost H; Grüneklee D; Korthaus G; Gries FA
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():835-8. PubMed ID: 1029295
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
    MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 17. Growth hormone secretion in primary endogenous hypertriglyceridemia.
    Muggeo M; Fedele D; Tiengo A; Crepaldi G
    Horm Metab Res; 1973 May; 5(3):224-5. PubMed ID: 4714551
    [No Abstract]   [Full Text] [Related]  

  • 18. Metformin administration in hyperlipidemic states.
    Gustafson A; Björntorp P; Fahlén M
    Acta Med Scand; 1971 Dec; 190(6):491-4. PubMed ID: 5149092
    [No Abstract]   [Full Text] [Related]  

  • 19. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W; Kremer GJ; Müller D
    MMW Munch Med Wochenschr; 1975 Oct; 117(44):1783-6. PubMed ID: 171564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.